Ezetimibe
- Generic Name
- Ezetimibe
- Brand Names
- Ezetrol, Lypqozet, Nexlizet, Roszet, Vytorin, Zetia
- Drug Type
- Small Molecule
- Chemical Formula
- C24H21F2NO3
- CAS Number
- 163222-33-1
- Unique Ingredient Identifier
- EOR26LQQ24
- Background
Ezetimibe is a lipid-lowering compound that inhibits intestinal cholesterol and phytosterol absorption. The discovery and research of this drug began in the early 1990s, after the intravenous administration of radiolabelled ezetimibe in rats revealed that it was being localized within enterocytes of the intestinal villi - this prompted studies investigating ...
- Indication
Ezetimibe is indicated to reduce elevated total-C, LDL-C, Apo B, and non-HDL-C in patients with primary hyperlipidemia, alone or in combination with an HMG-CoA reductase inhibitor (statin). It is also indicated to reduce elevated total-C, LDL-C, Apo B, and non-HDL-C in patients with mixed hyperlipidemia in combination with fenofibrate, and to reduce elevated...
- Associated Conditions
- Elevated Blood Lipids, Elevated sitosterol and campesterol
- Associated Therapies
- -
Comparison of Ezetimibe Plus Simvastatin Versus Ezetimibe or Simvastatin Alone in Subjects With Primary Hypercholesterolemia (Study P03757)(COMPLETED)
- Conditions
- Interventions
- First Posted Date
- 2008-04-02
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 240
- Registration Number
- NCT00650819
Assessment of Potential Interaction Between Ezetimibe and Rosuvastatin in Healthy Subjects With High Cholesterol (P03317)
- Conditions
- Interventions
- First Posted Date
- 2008-04-02
- Last Posted Date
- 2022-02-17
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 40
- Registration Number
- NCT00651144
Ezetimibe Plus Atorvastatin Versus Atorvastatin Alone in Subjects With Primary Hypercholesterolemia (Study P03406)
- Conditions
- Interventions
- First Posted Date
- 2008-04-02
- Last Posted Date
- 2022-02-17
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 137
- Registration Number
- NCT00651404
Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood
- Conditions
- Interventions
- First Posted Date
- 2008-03-20
- Last Posted Date
- 2011-06-13
- Lead Sponsor
- Abbott
- Target Recruit Count
- 543
- Registration Number
- NCT00639158
The Influence of Ezetimibe on Gallbladder Function
- Conditions
- Interventions
- First Posted Date
- 2008-03-12
- Last Posted Date
- 2015-03-30
- Lead Sponsor
- Indiana University
- Registration Number
- NCT00634140
- Locations
- 🇺🇸
Indiana University Hospital, Indianapolis, Indiana, United States
Comprehensive Magnetic Resonance of Peripheral Arterial Disease
- Conditions
- Interventions
- First Posted Date
- 2008-01-07
- Last Posted Date
- 2017-08-21
- Lead Sponsor
- University of Virginia
- Target Recruit Count
- 85
- Registration Number
- NCT00587678
- Locations
- 🇺🇸
University of Virgina Health System, Charlottesville, Virginia, United States
12-week Open-label, Phase IIIb Comparing Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With Ezetimibe
- Conditions
- First Posted Date
- 2007-09-06
- Last Posted Date
- 2011-05-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1743
- Registration Number
- NCT00525824
- Locations
- 🇻🇪
Research Site, Brentwood, Venezuela
Effects of Ezetimibe Add-On to Statin Therapy on Adipokine Production in Obese and Metabolic Syndrome Patients With Atherosclerosis
- Conditions
- First Posted Date
- 2007-06-12
- Last Posted Date
- 2010-11-25
- Lead Sponsor
- Canadian Collaborative Research Network
- Target Recruit Count
- 50
- Registration Number
- NCT00485121
- Locations
- 🇨🇦
Partners Research, Brampton, Ontario, Canada
Effects of Statin and Ezetimibe Association on Kinetics of Artificial Chilomicrons
- Conditions
- Interventions
- First Posted Date
- 2007-06-01
- Last Posted Date
- 2011-01-26
- Lead Sponsor
- University of Sao Paulo
- Target Recruit Count
- 25
- Registration Number
- NCT00481351
Effect of Ezetimibe on Platelet Aggregation and LDL Tendency to Peroxidation
- Conditions
- First Posted Date
- 2007-04-27
- Last Posted Date
- 2013-02-20
- Lead Sponsor
- Ziv Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT00466401
- Locations
- 🇮🇱
Internal Medicine Department A ,Ziv Goverment Hospital, Safed, Israel
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.